Damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer onset in carriers of the harmful BRCA1 genetic mutation, reveal ...
Damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast ...
Myocardial infarction research reveals immune-driven cardiac damage. Learn how targeting NK cells could improve heart ...
They are called “Natural Killer” (NK) cells for a reason. These cytotoxic lymphocytes, a part of innate immunity, are the body’s cellular “boots on the ground,” capable of swiftly and ferociously ...
Findings may support development of more refined personalized breast cancer risk prediction models for BRCA1 pathogenic ...
Invariant natural killer T cells have emerged as a potentially versatile allogeneic platform for blood cancer immunotherapy, ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results